Piper Jaffray Companies set a $38.00 target price on Aimmune Therapeutics, Inc. (NASDAQ:AIMT) in a report published on Thursday. The firm currently has a buy rating on the biotechnology company’s stock.

A number of other research firms have also recently issued reports on AIMT. Zacks Investment Research cut Aimmune Therapeutics from a buy rating to a hold rating in a research note on Tuesday, July 11th. ValuEngine cut Aimmune Therapeutics from a hold rating to a sell rating in a research note on Saturday, May 27th. Finally, Wedbush reiterated an outperform rating and issued a $42.00 target price on shares of Aimmune Therapeutics in a research note on Monday, July 24th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the stock. The stock has an average rating of Buy and an average target price of $33.00.

Aimmune Therapeutics (NASDAQ:AIMT) opened at 21.60 on Thursday. The stock’s market cap is $1.09 billion. Aimmune Therapeutics has a 12 month low of $11.82 and a 12 month high of $27.31. The firm’s 50-day moving average is $20.35 and its 200-day moving average is $19.93.

Aimmune Therapeutics (NASDAQ:AIMT) last posted its earnings results on Monday, May 8th. The biotechnology company reported ($0.52) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.57) by $0.05. On average, equities analysts forecast that Aimmune Therapeutics will post ($2.66) earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Aimmune Therapeutics, Inc. (AIMT) PT Set at $38.00 by Piper Jaffray Companies” was first published by Watch List News and is owned by of Watch List News. If you are reading this news story on another domain, it was copied illegally and republished in violation of US and international copyright law. The legal version of this news story can be accessed at https://www.watchlistnews.com/aimmune-therapeutics-inc-aimt-pt-set-at-38-00-by-piper-jaffray-companies/1463246.html.

In related news, CFO Eric Bjerkholt acquired 5,000 shares of the business’s stock in a transaction that occurred on Friday, May 12th. The shares were acquired at an average cost of $19.84 per share, for a total transaction of $99,200.00. Following the completion of the purchase, the chief financial officer now directly owns 5,000 shares in the company, valued at $99,200. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Stephen George Dilly sold 50,000 shares of Aimmune Therapeutics stock in a transaction dated Wednesday, July 26th. The shares were sold at an average price of $21.46, for a total transaction of $1,073,000.00. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 188,570 shares of company stock worth $3,943,182. Company insiders own 24.56% of the company’s stock.

Several large investors have recently modified their holdings of AIMT. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in shares of Aimmune Therapeutics by 454.1% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,979 shares of the biotechnology company’s stock worth $130,000 after buying an additional 4,900 shares in the last quarter. Daiwa SB Investments Ltd. bought a new stake in shares of Aimmune Therapeutics during the first quarter worth $132,000. American International Group Inc. boosted its stake in shares of Aimmune Therapeutics by 7.1% in the first quarter. American International Group Inc. now owns 16,184 shares of the biotechnology company’s stock worth $352,000 after buying an additional 1,070 shares in the last quarter. Nationwide Fund Advisors boosted its stake in shares of Aimmune Therapeutics by 23.7% in the first quarter. Nationwide Fund Advisors now owns 20,095 shares of the biotechnology company’s stock worth $437,000 after buying an additional 3,851 shares in the last quarter. Finally, Franklin Street Advisors Inc. NC bought a new stake in shares of Aimmune Therapeutics during the first quarter worth $450,000. Institutional investors and hedge funds own 69.61% of the company’s stock.

About Aimmune Therapeutics

Aimmune Therapeutics, Inc is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company’s therapeutic approach, which it refers to as Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services.

Receive News & Ratings for Aimmune Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.